

Brain Hypoxia Is Associated With Short-term Outcome After Severe Traumatic Brain Injury Independently of Intracranial Hypertension and Low Cerebral Perfusion Pressure

Mauro Oddo, MD*‡
 Joshua M. Levine, MD*§||
 Larami Mackenzie, MD§
 Suzanne Frangos, RN*
 François Feihl, MD¶
 Scott E. Kasner, MD, MSCE§
 Michael Katsnelson, MD§
 Bryan Pukenas, MD#
 Eileen Macmurtrie, RN*
 Eileen Maloney-Wilensky, MSN*
 W. Andrew Kofke, MD||
 Peter D. LeRoux, MD*

Departments of *Neurosurgery, §Neurology, ||Anesthesiology and Critical Care, and #Radiology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; ‡Department of Intensive Care Medicine and ¶Division of Pathophysiology, Lausanne University Medical Center, Lausanne, Switzerland

Correspondence:

Peter D. LeRoux, MD,
 Department of Neurosurgery,
 Clinical Research Division,
 University of Pennsylvania
 Medical Center,
 330 S 9th St,
 Philadelphia, PA 19107.
 E-mail: peter.leroux@uphs.upenn.edu

Received, August 31, 2010.

Accepted, March 25, 2011.

Published Online, June 11, 2011.

Copyright © 2011 by the
 Congress of Neurological Surgeons

BACKGROUND: Brain hypoxia (BH) can aggravate outcome after severe traumatic brain injury (TBI). Whether BH or reduced brain oxygen (Pbto₂) is an independent outcome predictor or a marker of disease severity is not fully elucidated.

OBJECTIVE: To analyze the relationship between Pbto₂, intracranial pressure (ICP), and cerebral perfusion pressure (CPP) and to examine whether BH correlates with worse outcome independently of ICP and CPP.

METHODS: We studied 103 patients monitored with ICP and Pbto₂ for > 24 hours. Durations of BH (Pbto₂ < 15 mm Hg), ICP > 20 mm Hg, and CPP < 60 mm Hg were calculated with linear interpolation, and their associations with outcome within 30 days were analyzed.

RESULTS: Duration of BH was longer in patients with unfavorable (Glasgow Outcome Scale score, 1-3) than in those with favorable (Glasgow Outcome Scale, 4-5) outcome (8.3 ± 15.9 vs 1.7 ± 3.7 hours; $P < .01$). In patients with intracranial hypertension, those with BH had fewer favorable outcomes (46%) than those without (81%; $P < .01$); similarly, patients with low CPP and BH were less likely to have favorable outcome than those with low CPP but normal Pbto₂ (39% vs 83%; $P < .01$). After ICP, CPP, age, Glasgow Coma Scale score, Marshall computed tomography grade, and Acute Physiology and Chronic Health Evaluation II score were controlled for, BH was independently associated with poor prognosis (adjusted odds ratio for favorable outcome, 0.89 per hour of BH; 95% confidence interval, 0.79-0.99; $P = .04$).

CONCLUSION: Brain hypoxia is associated with poor short-term outcome after severe traumatic brain injury independently of elevated ICP, low CPP, and injury severity. Pbto₂ may be an important therapeutic target after severe traumatic brain injury.

KEY WORDS: Brain hypoxia, Brain tissue oxygen pressure, Cerebral perfusion pressure, Independent predictor, Intracranial Pressure, Outcome, Traumatic brain injury

Neurosurgery 69:1037-1045, 2011

DOI: 10.1227/NEU.0b013e3182287ca7

www.neurosurgery-online.com

Traumatic brain injury (TBI) remains a leading cause of death and disability among young people worldwide. Poor outcome is associated with delayed secondary cerebral damage that develops hours to days after

the initial insult. Brain hypoxia is a common cause of secondary cerebral damage after severe TBI.¹ Efforts to maintain adequate interstitial partial pressure of oxygen in brain tissue (Pbto₂) therefore may play an important role in the management of severe TBI patients. Pbto₂ may be monitored continuously at the bedside; the use of Pbto₂ monitors was recently incorporated into the guidelines for severe traumatic brain injury² on the basis of the notion that brain hypoxia, defined by a Pbto₂ < 15 mm Hg, may be diagnosed and corrected before irreversible damage occurs.³

ABBREVIATIONS: AOR, adjusted odds ratio; APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval; CPP, cerebral perfusion pressure; GCS, Glasgow Coma Scale; ICP, intracranial pressure; IQR, interquartile range; MAP, mean arterial pressure; TBI, traumatic brain injury

Previous clinical observations demonstrate an association between brain hypoxia and outcome after severe TBI.⁴⁻⁶ Overall, these studies include few patients but suggest that brain hypoxia may be an independent factor associated with poor outcome. Work by van den Brink et al⁴ suggests that the effect of brain hypoxia is independent of intracranial hypertension. However, it remains to be fully elucidated whether brain hypoxia is simply a marker of injury severity and its effects depend on intracranial pressure (ICP) and cerebral perfusion pressure (CPP) or whether the association between PbtO₂ and outcome is independent of the morphological and physiological effects of TBI, including those from increased ICP or reduced CPP.^{7,8}

In this study, we examined 103 patients who had both continuous PbtO₂ and ICP monitoring for at least 24 hours after severe nonpenetrating TBI. We hypothesized that brain hypoxia is associated with worse short-term outcome after severe TBI and that this association is independent of intracranial hypertension, low CPP, and the morphological or physiological consequences of the TBI. In addition, we used a linear interpolation method to examine the origin of secondary brain hypoxic insults and the relationship among reduced PbtO₂, elevated ICP, and low CPP.

METHODS

Patients

Subjects included in this study were identified retrospectively from a prospective observational database (Brain Oxygen Monitoring Outcome study) that describes patients with severe TBI treated in the neurointensive care unit at the Hospital of the University of Pennsylvania, Philadelphia, an academic level 1 trauma center. Approval for the study was obtained from the Institutional Review Board. Traumatic brain injury was defined by a history of trauma and clinical and radiographic exclusion of alternative causes of coma. Patients included in this study had nonpenetrating TBI and both PbtO₂ and ICP monitoring if at any time during hospitalization their Glasgow Coma Scale (GCS) score was ≤ 8 . Patients were excluded who had fixed and dilated pupils at admission, had < 24 hours of intracranial monitoring, had PbtO₂ = 0 mm Hg for > 3 hours, or were declared brain dead within 48 hours of initiation of monitoring.

Intracranial Monitoring

Intracranial pressure, brain temperature, and PbtO₂ were monitored continuously with a Licox monitor (Integra Neuroscience, Plainsboro, New Jersey) as part of standard patient care when their GCS was ≤ 8 .⁹ All 3 intracranial monitors were inserted at the bedside through the same burr hole into the frontal lobe and secured with a triple-lumen bolt. The PbtO₂ monitor was placed into white matter that appeared normal on the admission head computed tomography (CT) and on the side of maximal pathology. When there was no asymmetry in brain pathology on CT, the probes were placed in the right frontal region. If the patient had undergone a craniotomy, the probes were placed on the same side as the injury if the craniotomy flap permitted. Follow-up noncontrast head CT scans were performed in all patients within 24 hours of admission to confirm correct placement of the various monitors, eg, not in a contusion or infarct. Probe function and stability were confirmed by an oxygen challenge (Fio₂, 1.0 for 2 minutes). To allow for probe equilibration, data

from the first 3 hours after ICP and PbtO₂ monitor insertion were discarded. Each patient also had an indwelling arterial (usually radial artery) catheter, and mean arterial pressure (MAP) was recorded continuously in all patients. Cerebral perfusion pressure was calculated from the measured parameters (CPP = MAP – ICP). Heart rate and arterial oxygen saturation (Sao₂) also were recorded in all patients. Intracranial monitors were removed when ICP was normal for 24 hours without treatment or when the patient was able to follow commands.

General Clinical Management

All patients were resuscitated and managed according to a protocol based on published recommendations for severe TBI and intensive care unit (ICU) care.¹⁰ This included (1) early identification and evacuation of traumatic hematomas; (2) intubation and ventilation with low-volume pressure-limited ventilation to maintain Paco₂ between 30 and 40 mm Hg and Sao $> 93\%$; (3) sedation with propofol during the first 24 hours, followed by sedation and analgesia with lorazepam, morphine, or fentanyl; (4) bed rest with head elevation initially of $\geq 30^\circ$; (5) normothermia of approximately 35°C to 37°C; (6) euvolemia using a baseline crystalloid infusion (0.9% normal saline, 20 mEq/L KCl; 80-100 mL/h); (7) anticonvulsant prophylaxis with phenytoin for ≥ 1 week if seizures occurred; and (8) packed red blood cell transfusion if their hemoglobin was < 7 mg/dL. Goals of therapy included maintaining ICP < 20 mm Hg and CPP > 60 mm Hg.

Management of Intracranial Hypertension

Elevated ICP (> 20 mm Hg for > 2 minutes) was initially treated with elevation of the head of the bed, sedation (lorazepam), and analgesia (fentanyl). If ICP remained > 20 mm Hg for > 10 minutes despite these initial measures, osmotherapy was administered using repeated boluses of mannitol (1 g/kg, 25% solution), provided that the serum osmolar gap was < 20 . Thereafter, cerebrospinal fluid was drained with an external ventricular drain, particularly if there was hydrocephalus. Second-tier therapies for refractory intracranial hypertension (> 20 mm Hg for > 15 minutes in a 1-hour period despite therapy) included optimized hyperventilation (Paco₂, 30-35 mm Hg), decompressive craniectomy, or pharmacological coma (with propofol or pentobarbital). Induced hypothermia and hypertonic saline for ICP control were not used to manage ICP in the patients included in this study. Therapeutic intensity level was calculated as previously described,¹¹ and for each patient, we analyzed the correlation between the maximum therapeutic intensity level and both the duration of brain hypoxia and elevated ICP.

Management of Brain Oxygen

Patients received “cause”-directed therapy to maintain PbtO₂ ≥ 20 mm Hg according to our local protocol.^{9,12} When PbtO₂ was low in the setting of intracranial hypertension (ICP > 20 mm Hg), measures were taken to lower ICP as described above. If ICP < 20 mm Hg or lowering ICP failed to raise PbtO₂, then CPP was increased (usually with phenylephrine). If the cause of low PbtO₂ was systemic hypoxia, then pulmonary function was optimized with the mechanical ventilator (eg, by increasing Fio₂ and/or positive end-expiratory pressure). If excess metabolic demand was suspected (eg, owing to pain, agitation, fever, or seizures), then analgesic, sedative, or antiepileptic medications were administered. If these measures failed and hemoglobin was < 10 mg/dL, then a blood transfusion was administered. A decompressive craniectomy was considered if there was a progressive PbtO₂ decline or PbtO₂ was ≤ 20 mm Hg for > 15 minutes despite maximal medical management for elevated ICP.

Data Collection and Analysis

Clinical and radiological variables included age, admission (post-resuscitation) GCS, Acute Physiology and Chronic Health Evaluation (APACHE) II score, and Marshall CT scan classification.^{13,14} Marshall CT classification was determined by consensus of a neurointensivist, a neuroradiologist, and a non-ICU neurologist who examined admission head CT scans in random order and who were blinded to patient outcome. Presence/absence of traumatic subarachnoid hemorrhage and intraventricular hemorrhage was also assessed on the CT scan. Clinical information was obtained from patient hospital records. Detailed information on prehospital care was unavailable.

Physiological variables, including P_{btO₂}, ICP, MAP, and CPP, were monitored continuously at the bedside (Component Monitoring System M1046-9090C, Hewlett Packard, Andover, Massachusetts) and were recorded in the ICU flow sheet usually every 15 minutes and at least every 30 minutes. Thresholds of physiological abnormality were defined as follows: P_{btO₂} < 15 mm Hg,² ICP > 20 mm Hg¹⁵, and CPP < 60 mm Hg.¹⁶ These thresholds were chosen to be consistent with current recommendations in the guidelines for the management of severe traumatic brain injury. Brain hypoxia was defined as a P_{btO₂} < 15 mm Hg of > 30 minutes in duration.² Because of the large and variable number of repeated physiological measurements and abnormal episodes over the duration of monitoring, for each individual patient, single episodes of physiological abnormality were identified and their duration was determined with linear interpolation¹⁷ (Figure 1). This method allowed us to measure the total duration (sum of the duration of single episodes) of low P_{btO₂} < 15 mm Hg, elevated ICP > 20 mm Hg, and low CPP < 60 mm Hg. The relationship between P_{btO₂} and CPP was further analyzed within each individual patient by calculating the total time during which episodes of brain hypoxia and CPP < 60 mm Hg occurred simultaneously and the percentage of brain hypoxic time with normal CPP ≥ 60 mm Hg.




FIGURE 1. Definitions and calculations related to a single episode of physiological abnormality. The y with indexes designates successive recorded values of the physiological variable, whether brain tissue oxygen tension (P_{btO₂}), intracranial pressure (ICP), or cerebral perfusion pressure (CPP). Each y falls either on the physiological side or on the abnormal side of a threshold value (ie, ICP > 20 mm Hg, CPP < 60 mm Hg, P_{btO₂} < 15 mm Hg; dotted line). A single episode is a sequence of successive values, each beyond threshold. The figure illustrates an example of abnormal physiological episode, with the last normal value before the episode (y_0), the first (y_1) and last (y_n) value falling within the episode, and the first normal value after the episode (y_{n+1}), with t_0 , t_1 , t_n , and t_{n+1} being the corresponding times. The episode time boundaries T_1 and T_e are determined by linear interpolation as shown. If the time interval separating y_1 from y_0 ($t_1 - t_0$) exceeded 2 hours, T_1 was set equal to t_1 . The same rule applies to the determination of T_e . Duration of the abnormal physiological value equals the time between T_1 and T_e .

Cause of Secondary Brain Hypoxic Insults

For each patient, we determined the cause of every brain hypoxic episode. The cause of brain hypoxia was classified as follows: (1) CPP decrease of at least 10 mm Hg, resulting from either ICP increases > 20 mm Hg (low CPP/high ICP) or MAP decreases of at least 10 mm Hg (low CPP/low MAP); (2) P_{aO₂} < 90 mm Hg; (3) hemoglobin concentration < 9 g/dL; (4) hyperthermia > 38.3°C or induced cooling; and (5) unknown/unidentifiable, in cases when we were unable to find the exact cause of brain hypoxia.

Outcome Assessment

A neurointensivist and a neurocritical nurse independently assessed short-term outcome within 30 days of injury. Outcome was assessed with the Glasgow Outcome Scale score dichotomized as favorable (Glasgow Outcome Scale score of 4 = moderate disability or 5 = good recovery) or unfavorable (Glasgow Outcome Scale score of 1 = death, 2 = vegetative state, and 3 = severe disability requiring long-term rehabilitation facility or skilled nursing facility).

Statistical Analysis

Statistical analysis was performed with the Stata 9 software package (StataCorp LP, College Station, Texas). A value of $P < .05$ was considered statistically significant. To examine associations between clinical, radiological, and physiological variables and outcome, univariate comparisons were performed with the Student t or Mann-Whitney U test (for continuous variables and according to the distribution of the data) or the χ^2 test (for categorical variables). The following variables were analyzed: age, admission GCS, Marshall CT classification, APACHE II score (without GCS inclusion), duration of brain hypoxia, elevated ICP, and low CPP. All variables with a significance level < .2 on univariate analysis were candidates for inclusion in a multivariable logistic regression model in which the dependent variable was the neurological outcome dichotomized as favorable or unfavorable. A stepwise forward approach was used for variable selection, with P values to include of .15 and P values to exclude of .2; therefore, only variables with a value of $P < .2$ were retained by the final model. Likelihood ratio test was used to compare the fit of the models.

RESULTS

Study Population

One hundred three patients (mean age, 43 ± 19 years) with severe TBI who were hospitalized between October 2002 and October 2005 were included in this study. Another 31 patients managed during the same time period were excluded from analysis because of penetrating TBI ($n = 10$), ICP and P_{btO₂} monitoring that lasted < 24 hours ($n = 8$), P_{btO₂} = 0 mm Hg with a confirmed diagnosis of brain death within 48 hours of the start of intracranial monitoring ($n = 8$), and incomplete data ($n = 5$). Individual patient clinical and radiological characteristics are summarized in Table 1. The majority of patients (79%) had traumatic subarachnoid hemorrhage or intraventricular hemorrhage on admission CT scan.

Prevalence of Brain Hypoxia, Elevated ICP, and Low CPP During Intracranial Monitoring

Data on P_{btO₂} and ICP monitoring are summarized in Table 2. The median time from admission to intracranial monitoring was

TABLE 1. Baseline Patient Characteristics^a

Characteristic	Study Population (n = 103)
Age, y	43 ± 19
Female sex, n (%)	23 (29)
Admission GCS, ^b n (%)	
3-4	52 (50)
5-6	15 (14)
7-8	16 (16)
> 8	20 (20)
Marshall head CT classification, n (%)	
2	21 (20)
3	31 (30)
4	8 (8)
5	43 (42)
APACHE II score, n (%)	
< 16	21 (20)
16-20	36 (35)
20-25	31 (30)
> 25	15 (15)

^aAPACHE II, Acute Physiology and Chronic Health Evaluation II; GCS, Glasgow Coma Scale. Data are expressed as mean ± SD when appropriate.

^bThe GCS listed is the postresuscitation GCS in the emergency room. Twenty patients had an initial GCS > 8 but subsequently deteriorated and required intracranial monitoring (ie, GCS ≤ 8).

6 hours (interquartile range [IQR], 3-13 hours). Median maximal therapeutic intensity level during intracranial monitoring was 8 (range, 5-18).

Etiology of Brain Hypoxic Insults

Figure 2 illustrates the suspected cause of brain hypoxia. A CPP decrease, because either ICP increased (low CPP/high ICP, 50%) or MAP decreased (low CPP/low MAP, 25%), was frequently associated with brain hypoxia. Our CPP threshold for treatment was 60 mm Hg; CPP was ≥ 60 mm Hg over a median

TABLE 2. Prevalence of Brain Hypoxia (Pbto₂ < 15 mm Hg), Intracranial Hypertension (Intracranial Pressure > 20 mm Hg), and Low Cerebral Perfusion Pressure (< 60 mm Hg) Over the Entire Duration of Intracranial Monitoring^a

Variable	
Duration of intracranial monitoring, d	5 ± 3
Patients with brain hypoxia, n (%)	55 (54)
Mean patient duration of brain hypoxia, h	8.6 ± 14.4
Patients with intracranial hypertension, n (%)	74 (73)
Mean patient duration of intracranial hypertension, h	24.8 ± 31.2
Patients with low CPP, n (%)	75 (74)
Mean patient duration of low CPP, h	10.2 ± 12.3

^aCPP, cerebral perfusion pressure. Data are expressed as mean ± SD when appropriate.

of 48% (IQR, 3%-93%) of brain hypoxic time. The wide interindividual range suggests that individual CPP thresholds for brain hypoxia vary between patients and may often be > 60 mm Hg. Other factors associated with brain hypoxia were hyperthermia (5%), induced cooling (7%), Pao₂ < 90 mm Hg (8%), and hemoglobin concentration < 9 g/dL (2%).

The Relationship Between Pbto₂, ICP, and CPP

The relationship between Pbto₂, ICP, and CPP was analyzed within the entire patient cohort (Table 3). Patients with elevated ICP and low CPP were more likely to have brain hypoxia (43 of 74 [58%] and 46 of 75 [61%], respectively), whereas Pbto₂ was always ≥ 15 mm Hg in many patients with normal ICP (16 of 28 [57%]) and normal CPP (18 of 28 [63%]). However, brain hypoxia also was observed in patients with normal ICP (12 of 28 [43%]) and in those with normal CPP (9 of 27 [33%]), whereas 31 of 74 patients (42%) with elevated ICP and 29 of 75 patients (39%) with low CPP had no episodes of Pbto₂ < 15 mm Hg. Therapeutic intensity level correlated with the duration of elevated ICP (Pearson *r* linear correlation coefficient, 0.53; *P* < .001) but not with the duration of brain hypoxia (*r* = 0.14, *P* = .29).

Factors Associated With Outcome

Favorable outcome (good recovery, n = 37, or moderate disability, n = 21) was observed in 58 patients (57%). Thirty-seven patients had died and 8 were vegetative or severely disabled at 30 days. The duration of monitoring was not associated with outcome (85 hours [IQR, 45-165 hours] in patients with favorable vs 77 hours [IQR, 46-113 hours] in those with unfavorable outcome; *P* = .17, Mann-Whitney *U* test). Time to monitoring was also comparable between the 2 outcome groups (6 hours [IQR, 3-16 hours] vs 7 hours [IQR, 4-11 hours]; *P* = .93, Mann-Whitney *U* test).




FIGURE 2. Cause of brain hypoxic insults. Histograms illustrate the potential causes of brain hypoxia classified as follows: (1) cerebral perfusion pressure (CPP) decrease of at least 10 mm Hg, either because intracranial pressure (ICP) increased > 20 mm Hg (low CPP/high ICP) or because mean arterial pressure (MAP) decreased at least 10 mm Hg (low CPP/low MAP); (2) Pao₂ < 90 mm Hg; (3) hemoglobin concentration < 9 g/dL; (4) hyperthermia > 38.3°C or induced cooling; or (5) unknown/unidentifiable, ie, unable to find the exact cause of brain hypoxia.

TABLE 3. Number of Patients With High vs Normal Intracranial Pressure and With Low vs Normal Cerebral Perfusion Pressure Expressed as a Function of PbtO₂ Values^a

	Patients With ICP > 20 mm Hg	Patients With ICP 0 – 20 mm Hg
Patients with PbtO ₂ < 15 mm Hg (n = 55)	43	12
Patients with PbtO ₂ ≥ 15 mm Hg (n = 47)	31	16
Total (n = 102)	74	28

	Patients With CPP < 60 mm Hg	Patients With CPP ≥ 60 mm Hg
Patients with PbtO ₂ < 15 mm Hg (n = 55)	46	9
Patients with PbtO ₂ ≥ 15 mm Hg (n = 47)	29	18
Total (n = 102)	75	27

^aCPP, cerebral perfusion pressure; ICP, intracranial pressure. Data on ICP and CPP were incomplete in 1 patient.

Table 4 lists univariate associations between outcome and all clinical, radiological, and physiological variables. Age, admission GCS, Marshall CT classification, APACHE II score, duration of brain hypoxia, and high ICP were significantly associated with outcome. Alone, the duration of low CPP was not associated with outcome. However, Table 4 also shows that time when CPP < 60 mm Hg occurred simultaneously with PbtO₂ < 15 mm Hg was longer in patients with an unfavorable than in those with a favorable outcome, thereby suggesting that low CPP has significant prognostic value, particularly when it is associated with brain hypoxia. A similar association between the duration of brain hypoxia and outcome was found when only the first 24 hours

of intracranial monitoring were examined (0.7 ± 1.8 hours in patients with favorable vs 4.2 ± 8.8 hours in those with unfavorable outcome; $P < .001$).

Brain Hypoxia and Outcome

We further examined the impact of brain hypoxia on outcome in the subgroup of patients with intracranial hypertension and low CPP (Table 5). When there was intracranial hypertension, the presence of brain hypoxia was associated with fewer favorable outcomes (46% vs 81% in patients with high ICP but normal PbtO₂; $P < .01$). Similarly, in patients who had both low CPP and brain hypoxia, 39% had a favorable outcome vs 83% of those with low CPP but normal PbtO₂ ($P < .01$).

Brain Hypoxia Is Associated With Outcome After Severe TBI

All variables with a significance level < .2 on univariate analysis (Table 4) were included in a multivariable logistic regression model. A stepwise forward approach was used for variable selection with P values to include of .15 and P values to exclude of .2. Likelihood ratio test was used to compare the fit of the models. Only variables with a value of $P < .2$ were retained in the final multivariable model (Table 6). With this model, brain hypoxia was an independent predictor of poor prognosis in our cohort of severe TBI, with an adjusted odds ratio (AOR) for favorable outcome of 0.89 (95% confidence interval [CI], 0.79-0.99) per hour spent with a PbtO₂ < 15 mm Hg ($P = .04$). Other factors associated with outcome in multivariable analysis included Marshall CT classification (AOR, 0.42; 95% CI, 0.25-0.71; $P = .01$), admission GCS (AOR, 1.21; 95% CI, 1.02-1.44; $P = .03$), and APACHE II score (AOR, 0.86; 95% CI, 0.73-1.00; $P = .05$). Intracranial hypertension (duration of ICP > 20 mm Hg) was retained as a prognostic predictor by the final model, although it did not reach statistical significance (AOR for favorable outcome, 0.99 per hour of ICP > 20 mm Hg; 95% CI, 0.98-1.01; $P = .11$).

TABLE 4. Factors Associated With Outcome on Univariate Analysis^a

Variable	Favorable Outcome (GOS, 4-5) (n = 58)	Unfavorable Outcome (GOS, 1-3) (n = 45)	P
Age, y	38 (26-51)	47 (28-69)	< .01 ^b
Admission GCS	6 (3-9)	3 (3-6)	< .01 ^b
Marshall CT classification (admission)	3 (2-4)	5 (3-5)	< .001 ^b
APACHE II score	17 (15-21)	22 (19-25)	< .001 ^b
PbtO ₂ < 15 mm Hg duration, h	1.7 ± 3.7	8.3 ± 15.9	< .01 ^b
ICP > 20 mm Hg duration, h	11.5 ± 16.5	21.6 ± 29.6	.03 ^b
CPP < 60 mm Hg duration, h	6.5 ± 9.7	8.2 ± 8.3	.35
CPP < 60 mm Hg + PbtO ₂ < 15 mm Hg duration, h	0.8 ± 2.3	3.3 ± 7.4	.02 ^b

^aAPACHE II, Acute Physiology and Chronic Health Evaluation II; CPP, cerebral perfusion pressure; GCS, Glasgow Coma Scale; GOS, Glasgow Outcome Scale; ICP, intracranial pressure. Using a linear interpolation method, we calculated for each patient the total duration of brain hypoxia (defined by a PbtO₂ < 15 mm Hg), high ICP (defined by an ICP > 20 mm Hg), and low CPP (defined by a CPP < 60 mm Hg). Total duration of episodes when low CPP and low PbtO₂ occurred simultaneously also is provided. Data are expressed as median (interquartile range) or mean ± SD.

^bSignificant.

TABLE 5. Outcome in Patients With Intracranial Hypertension (Intracranial Pressure > 20 mm Hg) and Low Cerebral Perfusion Pressure (< 60 mm Hg) According to the Presence or Absence of Brain Hypoxia (Pbto₂ < 15 mm Hg)^a

	Patients With Favorable Outcome, n (%)	
	Intracranial Hypertension (n = 74)	Low CPP (n = 75)
Brain hypoxia	20/43 (46)	18/46 (39)
No brain hypoxia	25/31 (81)	24/29 (83)
P	< .01	< .01

^aCPP, cerebral perfusion pressure.

DISCUSSION

In this retrospective analysis of a prospective observational cohort of 103 severe TBI patients who had an ICP and Pbto₂ monitor for > 24 hours, we examined whether short-term outcome after severe TBI is associated with brain hypoxia (Pbto₂ < 15 mm Hg) independently of high ICP (> 20 mm Hg) and low CPP (< 60 mm Hg). The important finding of this study is that brain hypoxia (low Pbto₂ < 15 mm Hg) is associated with poor short-term outcome after severe TBI independently of elevated ICP and low CPP. This finding seems to suggest that Pbto₂ may be a better physiological prognostic marker than ICP and CPP in patients with severe TBI. We also observed that although brain hypoxia can be associated with a decrease in CPP, brain hypoxia may occur despite CPP being within normal ranges

TABLE 6. Independent Predictors of Outcome by Multivariable Analysis^a

Variable	Adjusted OR for Favorable Outcome	95% CI	Adjusted P
Marshall CT classification	0.42	0.25-0.71	.01 ^e
Admission GCS	1.21	1.02-1.44	.03 ^e
APACHE II score ^b	0.86	0.73-1.00	.05 ^e
Brain hypoxia ^c	0.89	0.79-0.99	.04 ^e
Intracranial hypertension ^d	0.99	0.98-1.01	.11

^aAPACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval; GCS, Glasgow Coma Scale; OR, odds ratio. All variables with a significance level < .2 on univariate analysis were included in a multivariable logistic regression model in which the dependent variable was the neurological outcome at 30 days dichotomized as favorable (Glasgow Outcome Scale [GOS], 4 [moderate disability], and 5 [good recovery]) or unfavorable (GOS, 1 [death], 2 [vegetative state], and 3 [severe disability]). A stepwise forward approach was used for variable selection, with P values to include of .15 and to exclude of .2. Variables with P > .2 (age, low CPP) therefore are not shown in the final model. The adjusted OR for favorable outcome was 0.89 per hour of brain hypoxia.

^bAPACHE II score was calculated without the inclusion of GCS.^cDuration of Pbto₂ < 15 mm Hg.^dDuration of intracranial pressure > 20 mm Hg.^eSignificant.

and greater than the usual therapeutic threshold. In addition, brain hypoxia was associated with unfavorable outcome independently of other known predictors of outcome, including age, admission GCS, Marshall grade, and APACHE II score, thereby suggesting that Pbto₂ may be a reasonable therapeutic target in some severe TBI patients. Taken together, our data support the use of Pbto₂ monitors after severe TBI and warrant further study to evaluate whether strategies to prevent and treat brain hypoxia may help improve TBI outcome.

The Need for Pbto₂ Monitors

In recent years, the use of Pbto₂ monitors has increased in the management of TBI patients.^{2,3} Data from other clinical studies in which alternative techniques such as cerebral microdialysis, positron emission tomography, and retrograde jugular catheters were used demonstrate that brain hypoxia or cell metabolic dysfunction may occur in the absence of ischemia and when CPP is normal.¹⁸⁻²⁰ We previously observed that one-third of severe TBI patients who are adequately resuscitated according to established guidelines still have evidence for brain hypoxia in the early hours after TBI.²¹ Similarly, a recent retrospective series of 27 TBI patients²² suggested that elevated ICP and/or low CPP are not the only causes of reduced Pbto₂ after severe TBI. Prospective observational studies demonstrate that fewer than half the episodes of brain hypoxia after TBI are associated with low CPP resulting from either increased ICP or decreased MAP²³ and that metabolic changes, eg, lactate elevation, may precede the increase in ICP.²³ In the present study, a CPP decrease was a frequent cause of brain hypoxia, together with low Pao₂, hyperthermia, induced cooling, and low hemoglobin concentration. In many instances, several factors occurred together. However, the CPP was ≥ 60 mm Hg during a median of 48% of brain hypoxic time. The wide interindividual range (3%-93%) suggests that individual CPP thresholds for brain hypoxia varies between patients and in many patients may be > 60 mm Hg. Together, these data suggest that some secondary brain hypoxic insults may go undetected if ICP and CPP are monitored alone. This supports the use of both ICP and Pbto₂ monitors to help optimize the management of severe TBI patients.

Pbto₂ Is an Independent Factor Associated With Severe TBI Outcome

Observational clinical TBI studies demonstrate a significant association between brain hypoxia and both mortality and unfavorable outcome.^{4-6,24} Only 1 study, however, found that brain hypoxia was associated with outcome independently of elevated ICP. We found that brain hypoxia was strongly associated with an unfavorable short-term outcome regardless of high ICP and low CPP and independently of important clinical prognostic determinants (ie, age, admission GCS, Marshall CT classification, and APACHE II score; see Table 6). In addition, our data suggest that after severe TBI, Pbto₂ levels may be a better physiological variable to predict outcome than ICP or CPP in some patients.

The Role of ICP and CPP

Intracranial pressure monitors are the “gold standard” used to monitor patients with severe TBI. There is a well-described relationship between mortality and high ICP (> 20 mm Hg) after severe TBI; however, the effectiveness of ICP-guided care has yet to be confirmed in a clinical trial, and 1 retrospective study suggests that some patients may not benefit from ICP-targeted therapy.²⁵ Similarly, CPP-based care does not always improve outcome because therapies to maintain CPP > 70 mm Hg may be associated with lung injury.²⁶ Consequently, the optimal CPP treatment threshold remains unclear. Current severe TBI management guidelines recommend a CPP between 50 and 70 mm Hg.¹⁶ In this study, the threshold for low CPP was set at 60 mm Hg to reflect these recommendations and our local practices for CPP management. A CPP threshold between 50 and 70 mm Hg may not be sufficient to prevent cerebral hypoxia/ischemia in all TBI patients.²⁷ In addition, how CPP is managed, eg, the Lund concept, may affect whether there is secondary injury. This has led to the concept of individualized CPP management, guided by CPP-correlated variations of PbtO₂ in the early phase after TBI.²⁸ In the present study, several observations lend support to a management strategy of “individualized CPP and PbtO₂-guided care”²⁸: (1) Normal ICP and CPP after severe TBI do not always exclude brain hypoxia; (2) although a CPP decrease is a common cause of brain hypoxia, CPP was ≥ 60 mm Hg in approximately half of brain hypoxic time, suggesting that the CPP threshold for brain hypoxia varies widely between individual subjects; (3) other factors (ie, low Pao₂, low hemoglobin concentration, hyperthermia, induced cooling) can cause brain hypoxia; (4) although elevated ICP alone is associated with unfavorable outcome,^{7,8} this association loses independent prognostic significance when ICP is controlled for PbtO₂; and (5) low CPP < 60 mm Hg is associated with unfavorable outcome only when it occurs simultaneously with brain hypoxia. These findings have 2 important clinical implications: PbtO₂ may be a better physiological marker of TBI outcome than ICP and CPP in some patients, and low CPP is not detrimental per se but may be detrimental when it causes brain hypoxia. Our data do not imply that an ICP monitor or ICP/CPP treatment is not needed after TBI. Ideally, all 3 parameters should be monitored because elevated ICP or low CPP may be one cause of reduced PbtO₂, as was the case in many patients in our study (Table 3). The use of a PbtO₂ monitor should complement an ICP monitor, and if data from several monitors are synthesized, then therapy may be targeted to patient-specific pathophysiology. We and others have demonstrated that PbtO₂ data also may help to target other therapies, eg, red blood cell transfusion^{29,30} or treatment of elevated ICP,³¹⁻³⁴ or to guide individual CPP management, thereby limiting secondary brain hypoxic insults.^{28,35,36} Although these findings support the concept of incorporating PbtO₂ data into clinical management strategies, the literature on the impact of PbtO₂-directed therapy on outcome is conflicting.³⁷⁻⁴⁰ Randomized trials therefore are required to define whether a PbtO₂-directed strategy improves outcome after severe TBI.

Methodological Limitations

Our study has several potential limitations. First, the data were examined retrospectively, and this may bias our results. However, the data were collected prospectively and analyzed with linear interpolation methods to calculate total time of brain hypoxia and with robust statistical methods. In particular, when the impact of physiological parameters on outcome is assessed, the use of linear interpolation method to calculate the total time of physiological abnormalities provides greater insight into the relationship than simply calculation of absolute mean or median values.^{17,41} Thus, we believe that the method used strengthens the main findings of our study. Second, the study was performed on patients treated at a single institution, so it may lack external validity. However, each patient was treated according to a standardized protocol consistent with the Guidelines for Severe Traumatic Brain Injury used in most level 1 trauma centers, and therapeutic intensity level was assessed. Third, we analyzed short-term outcome because only 30-day outcome was collected prospectively in this data set. This time point is valid for analysis of ICU processes of care such as ours. Although this time point may be sufficient to differentiate outcomes of general ICU patients, it may not be sufficient to reflect TBI recovery when functional outcome is more important and can occur with time. Fourth, the duration of monitoring differed among patients. This may be a potential confounding variable with an effect in both directions. However, the duration of monitoring was similar between patients with favorable or unfavorable outcome. In addition, when analysis was limited to the first 24 hours, the relationship between brain hypoxia and poor outcome remained. These findings suggest that duration of monitoring may not influence our results. Fifth, the sample size and number of events per predictor in the final statistical model are relatively small. This may mean that some important variables are excluded or are relevant only in our particular cohort of patients. In addition, the small sample size limits an investigation between variables. For that reason, we can conclude only that brain hypoxia appears to be an independent factor associated with poor short-term outcome. Sixth, the PbtO₂ monitor we used samples a limited volume of tissue around its tip; ie, it measures regional PbtO₂ and may not always reflect global brain oxygenation. Similarly, ICP monitors (and so CPP measurements) also may be considered “local” monitors in some patients⁴²; ie, global intracranial physiology may be difficult to monitor precisely with current intracranial monitors. However, clinical studies suggest that regional PbtO₂ reflects global brain tissue oxygenation when the monitor is located in uninjured brain,^{43,44} as in the present study. Importantly, with the monitor system we used, the ICP and PbtO₂ monitors are virtually in the same location; thus, the 2 data points likely reflect the same underlying pathology. Seventh, the PbtO₂ probes were placed in normal-appearing brain tissue on admission CT, not in pericontusional areas. This may have led to an underestimate of the extent of brain hypoxia, at least in patients with focal injury.⁴⁵ In addition, outcome may depend in part on where the probe is located relative to pathology. Eighth, the main determinants of

Pbto₂ in humans are only beginning to be elucidated. Whether Pbto₂ reflects oxygen diffusion, oxygen extraction, or oxygen accumulation in the brain⁴⁶⁻⁴⁸ remains unknown. It appears, however, that Pbto₂ is not simply a measure of cerebral blood flow.⁴⁹ We did not measure cerebral blood flow, oxygen extraction fraction, or cerebral metabolic rate of oxygen; thus, we cannot comment on why brain hypoxia developed and whether/which underlying causes are associated with outcome. Because CPP augmentation may improve Pbto₂ in some patients,³⁶ it is likely that Pbto₂ < 15 mm Hg represents cerebral ischemia, at least under certain conditions in some patients. Finally, there are several reported thresholds for brain hypoxia or when to initiate therapy for brain hypoxia. Because the main purpose of the present study was to analyze the impact of brain hypoxia on short-term outcome, we chose a threshold of Pbto₂ < 15 mm Hg, consistent with the present definitions of brain tissue hypoxia from the Brain Trauma Foundation guidelines.² It is conceivable that the results may be different if different thresholds were used, but we think this is unlikely on the basis of the experience with brain oxygen monitors in TBI to date.¹² The present study also is not a pure observational study because we treated brain oxygen when it was < 20 mm Hg, and how a patient responds to therapy may influence outcome.¹² Our results therefore may be interpreted to mean that those patients who do not respond to therapy to correct Pbto₂ are likely to do poorly rather than that the total burden of brain hypoxia is associated with outcome.

CONCLUSION

Brain hypoxia (Pbto₂ < 15 mm Hg) is frequent in patients with severe TBI, and although it may be caused by a decrease in CPP or an increase in ICP, brain hypoxia also occurs in patients in whom ICP and CPP are normal. Furthermore, the CPP threshold for brain hypoxia varies widely between subjects, and Pbto₂ may be < 15 mm Hg despite CPP being ≥ 60 mm Hg. In our patient cohort, brain hypoxia was associated with an unfavorable short-term outcome independently of elevated ICP, low CPP, and the severity of cerebral and systemic injury. Our data suggest that Pbto₂ is an important physiological target after severe TBI to complement ICP and CPP and to help guide the management of TBI patients. Further studies are needed to examine whether Pbto₂-directed therapy improves outcome in patients with severe TBI.

Disclosures

Eileen Maloney-Wilensky and Peter D. LeRoux are members of Integra Life-sciences Speaker's Bureau. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.

REFERENCES

1. Coles JP. Regional ischemia after head injury. *Curr Opin Crit Care*. 2004;10(2):120-125.
2. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury, X: brain oxygen monitoring and thresholds. *J Neurotrauma*. 2007;24(Suppl 1):S65-S70.
3. Bhatia A, Gupta AK. Neuromonitoring in the intensive care unit, II: cerebral oxygenation monitoring and microdialysis. *Intensive Care Med*. 2007;33(8):1322-1328.
4. van den Brink WA, van Santbrink H, Steyerberg EW, et al. Brain oxygen tension in severe head injury. *Neurosurgery*. 2000;46(4):868-876.
5. van Santbrink H, Maas AI, Avezaat CJ. Continuous monitoring of partial pressure of brain tissue oxygen in patients with severe head injury. *Neurosurgery*. 1996;38(1):21-31.
6. Maloney-Wilensky E, Gracias V, Itkin A, et al. Brain tissue oxygen and outcome after severe traumatic brain injury: a systematic review. *Crit Care Med*. 2009;37(6):2057-2063.
7. Juul N, Morris GF, Marshall SB, Marshall LF. Intracranial hypertension and cerebral perfusion pressure: influence on neurological deterioration and outcome in severe head injury: the Executive Committee of the International Selfotel Trial. *J Neurosurg*. 2000;92(1):1-6.
8. Vik A, Nag T, Fredrikli OA, et al. Relationship of "dose" of intracranial hypertension to outcome in severe traumatic brain injury. *J Neurosurg*. 2008;109(4):678-684.
9. Oddo M, Nduom E, Frangos S, et al. Acute lung injury is an independent risk factor for brain hypoxia after severe traumatic brain injury. *Neurosurgery*. 2010;67(2):338-344.
10. Robertson CS. Critical care management of traumatic brain injury. In: Winn HR, ed. *Youmans Neurological Surgery*. 5th ed. Philadelphia, PA: Saunders; 2004:5103-5144.
11. Weiner GM, Lacey MR, Mackenzie L, et al. Decompressive craniectomy for elevated intracranial pressure and its effect on the cumulative ischemic burden and therapeutic intensity levels after severe traumatic brain injury. *Neurosurgery*. 2010;66(6):1111-1118.
12. Spiotta AM, Stiefel MF, Gracias VH, et al. Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury. *J Neurosurg*. 2010;113(3):571-580.
13. Maas AI, Hukkelhoven CW, Marshall LF, Steyerberg EW. Prediction of outcome in traumatic brain injury with computed tomographic characteristics: a comparison between the computed tomographic classification and combinations of computed tomographic predictors. *Neurosurgery*. 2005;57(6):1173-1182.
14. Marshall LF, Marshall SB, Klauber MR, et al. The diagnosis of head injury requires a classification based on computed axial tomography. *J Neurotrauma*. 1992;9(Suppl 1):S287-S292.
15. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury, VIII: intracranial pressure thresholds. *J Neurotrauma*. 2007;24(Suppl 1):S55-S58.
16. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury, IX: cerebral perfusion thresholds. *J Neurotrauma*. 2007;24(Suppl 1):S59-S64.
17. Hemphill JC III, Barton CW, Morabito D, Manley GT. Influence of data resolution and interpolation method on assessment of secondary brain insults in neurocritical care. *Physiol Meas*. 2005;26(4):373-386.
18. Le Roux PD, Newell DW, Lam AM, Grady MS, Winn HR. Cerebral arteriovenous oxygen difference: a predictor of cerebral infarction and outcome in patients with severe head injury. *J Neurosurg*. 1997;87(1):1-8.
19. Menon DK, Coles JP, Gupta AK, et al. Diffusion limited oxygen delivery following head injury. *Crit Care Med*. 2004;32(6):1384-1390.
20. Vespa P, Bergsneider M, Hattori N, et al. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. *J Cereb Blood Flow Metab*. 2005;25(6):763-774.
21. Stiefel MF, Udoetuk JD, Spiotta AM, et al. Conventional neurocritical care and cerebral oxygenation after traumatic brain injury. *J Neurosurg*. 2006;105(4):568-575.
22. Chang JJ, Youn TS, Benson D, et al. Physiologic and functional outcome correlates of brain tissue hypoxia in traumatic brain injury. *Crit Care Med*. 2009;37(1):283-290.
23. Adamides AA, Cooper DJ, Rosenfeldt FL, et al. Focal cerebral oxygenation and neurological outcome with or without brain tissue oxygen-guided therapy in patients with traumatic brain injury. *Acta Neurochir (Wien)*. 2009;151(11):1399-1409.
24. Valadka AB, Gopinath SP, Contant CF, Uzura M, Robertson CS. Relationship of brain tissue Po₂ to outcome after severe head injury. *Crit Care Med*. 1998;26(9):1576-1581.

25. Cremer OL, van Dijk GW, van Wensen E, et al. Effect of intracranial pressure monitoring and targeted intensive care on functional outcome after severe head injury. *Crit Care Med*. 2005;33(10):2207-2213.
26. Robertson CS, Valadka AB, Hannay HJ, et al. Prevention of secondary ischemic insults after severe head injury. *Crit Care Med*. 1999;27(10):2086-2095.
27. Coles JP, Steiner LA, Johnston AJ, et al. Does induced hypertension reduce cerebral ischaemia within the traumatized human brain? *Brain*. 2004;127(pt 11):2479-2490.
28. Jaeger M, Schuhmann MU, Soehle M, Meixensberger J. Continuous assessment of cerebrovascular autoregulation after traumatic brain injury using brain tissue oxygen pressure reactivity. *Crit Care Med*. 2006;34(6):1783-1788.
29. Oddo M, Milby A, Chen I, et al. Hemoglobin concentration and cerebral metabolism in patients with aneurysmal subarachnoid hemorrhage. *Stroke*. 2009;40(4):1275-1281.
30. Smith MJ, Stiefel MF, Magge S, et al. Packed red blood cell transfusion increases local cerebral oxygenation. *Crit Care Med*. 2005;33(5):1104-1108.
31. Francony G, Fauvage B, Falcon D, et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. *Crit Care Med*. 2008;36(3):795-800.
32. Oddo M, Levine JM, Frangos S, et al. Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension. *J Neurol Neurosurg Psychiatry*. 2009;80(8):916-920.
33. Jaeger M, Soehle M, Meixensberger J. Effects of decompressive craniectomy on brain tissue oxygen in patients with intracranial hypertension. *J Neurol Neurosurg Psychiatry*. 2003;74(4):513-515.
34. Stiefel MF, Heuer GG, Smith MJ, et al. Cerebral oxygenation following decompressive hemicraniectomy for the treatment of refractory intracranial hypertension. *J Neurosurg*. 2004;101(2):241-247.
35. Johnston AJ, Steiner LA, Chatfield DA, et al. Effect of cerebral perfusion pressure augmentation with dopamine and norepinephrine on global and focal brain oxygenation after traumatic brain injury. *Intensive Care Med*. 2004;30(5):791-797.
36. Johnston AJ, Steiner LA, Coles JP, et al. Effect of cerebral perfusion pressure augmentation on regional oxygenation and metabolism after head injury. *Crit Care Med*. 2005;33(1):189-195.
37. Narotam PK, Morrison JF, Nathoo N. Brain tissue oxygen monitoring in traumatic brain injury and major trauma: outcome analysis of a brain tissue oxygen-directed therapy. *J Neurosurg*. 2009;111(4):672-682.
38. Stiefel MF, Spiotta A, Gracias VH, et al. Reduced mortality rate in patients with severe traumatic brain injury treated with brain tissue oxygen monitoring. *J Neurosurg*. 2005;103(5):805-811.
39. Martini RP, Deem S, Yanez ND, et al. Management guided by brain tissue oxygen monitoring and outcome following severe traumatic brain injury. *J Neurosurg*. 2009;111(4):644-649.
40. Meixensberger J, Jaeger M, Vath A, Dings J, Kunze E, Roosen K. Brain tissue oxygen guided treatment supplementing ICP/CPP therapy after traumatic brain injury. *J Neurol Neurosurg Psychiatry*. 2003;74(6):760-764.
41. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. *JAMA*. 2008;300(4):413-422.
42. Schaller B, Graf R. Different compartments of intracranial pressure and its relationship to cerebral blood flow. *J Trauma*. 2005;59(6):1521-1531.
43. Gupta AK, Hutchinson PJ, Al-Rawi P, et al. Measuring brain tissue oxygenation compared with jugular venous oxygen saturation for monitoring cerebral oxygenation after traumatic brain injury. *Anesth Analg*. 1999;88(3):549-553.
44. Kiening KL, Unterberg AW, Bardt TF, Schneider GH, Lanksch WR. Monitoring of cerebral oxygenation in patients with severe head injuries: brain tissue P_{O_2} versus jugular vein oxygen saturation. *J Neurosurg*. 1996;85(5):751-757.
45. Longhi L, Pagan F, Valeriani V, et al. Monitoring brain tissue oxygen tension in brain-injured patients reveals hypoxic episodes in normal-appearing and in perifocal tissue. *Intensive Care Med*. 2007;33(12):2136-2142.
46. Hemphill JC III, Smith WS, Sonne DC, Morabito D, Manley GT. Relationship between brain tissue oxygen tension and CT perfusion: feasibility and initial results. *AJNR Am J Neuroradiol*. 2005;26(5):1095-1100.
47. Jaeger M, Soehle M, Schuhmann MU, Winkler D, Meixensberger J. Correlation of continuously monitored regional cerebral blood flow and brain tissue oxygen. *Acta Neurochir (Wien)*. 2005;147(1):51-56.
48. Scheufler KM, Rohrborn HJ, Zentner J. Does tissue oxygen-tension reliably reflect cerebral oxygen delivery and consumption? *Anesth Analg*. 2002;95(4):1042-1048, table of contents.
49. Rosenthal G, Hemphill JC III, Sorani M, et al. Brain tissue oxygen tension is more indicative of oxygen diffusion than oxygen delivery and metabolism in patients with traumatic brain injury. *Crit Care Med*. 2008;36(6):1917-1924.

COMMENT

Oddo et al make a clear case in this article that brain hypoxia, as defined by low brain tissue oxygen tensions, is associated with poorer short-term outcome in severe traumatic brain injury (TBI). The number of hypoxic episodes and summated duration of these episodes were shown to be independent predictors of unfavorable outcome as assessed by the Glasgow Outcome Scale at 30 days after injury. A major asset of this article is its clarity of presentation. This clarity, however, has come at a certain cost and necessitated perhaps an overly simplistic approach to the analysis of an extremely complex problem.

Confounding factors influencing the interpretation of the findings reported by Oddo et al lie particularly in the variability of duration of monitoring and the fact that treatment intensity was not reported. Taking these factors into consideration would necessitate a much more sophisticated approach to the statistical analysis. It may be argued that the finding of an increased duration of adverse episodes (low brain tissue P_{O_2} , high intracranial pressure [ICP], or low cerebral perfusion pressure [CPP]) in patients with poorer outcome might simply be interpreted as identifying nonresponders to treatment. This criticism is relevant because the treatment protocol for severe TBI as implemented in the study center included treatment of low $P_{bT_{O_2}}$, high ICP, and low CPP. I recall the barbiturate story in which Eisenberg et al¹ clearly showed that patients with elevated ICP responding to barbiturate administration have a much better outcome than patients not responding. The provision of summary information on the therapeutic intensity level for ICP as given in this study does not permit identification of responders versus non-responders. From both a scientific and a clinical perspective, reporting the number, type, and success of treatment modalities used when adverse episodes were detected would have provided great additional value. Such data might also have served to further support the concept that treatment of low brain tissue P_{O_2} is likely to improve outcome. As a consequence, despite the clear demonstration of an independent association between brain hypoxia and unfavorable short-term outcome in TBI, we are left with some degree of uncertainty concerning cause and effect. Although I would agree with the final statement in the conclusions that "[f]urther studies are needed to examine whether $P_{bT_{O_2}}$ -directed therapy improves outcome in patients with severe TBI," the evidence pointing in this direction is definitely accumulating.

Andrew I.R. Maa
Antwerp, Belgium

1. Eisenberg HM, Frankowski RF, Contant CF, et al. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. *J Neurosurg*. 1988;69(1):15-23.